



ZF W

Docket No.: NEL-0018/NP  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
R. Elaine Fulton et al.

Application No.: 10/784,305

Confirmation No.: 1520

Filed: February 24, 2004

Art Unit: 1648

For: GENETIC ENGINEERING OF  
STREPTAVIDIN-BINDING PEPTIDE  
TAGGED SINGLE-CHAIN VARIABLE  
FRAGMENT ANTIBODY TO VENEZUELAN  
EQUINE ENCEPHALITIS VIRUS

Examiner: S. B. Chen

**RESPONSE TO NOTICE OF NON-COMPLIANCE**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Notice of Non-Compliance dated December 23, 2005, Applicant hereby submits the enclosed Revised Amendment effecting the changes requested in the Notice.

Applicant believes no fee is due with this response. However, if a fee is due, please charge our Deposit Account No. 18-0013, under Order No. NEL-0018/NP (80283-0021) from which the undersigned is authorized to draw.

Dated: January 23, 2006

Respectfully submitted,

By

David T. Nikaido

Registration No.: 22,663

Lee Cheng

Registration No.: 40,949

RADER, FISHMAN & GRAUER PLLC

1233 20th Street, N.W.

Suite 501

Washington, DC 20036

(202) 955-3750

Attorneys for Applicant



Docket No.: NEL-0018/NP  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
R. Elaine Fulton et al.

Application No.: 10/784,305

Confirmation No.: 1520

Filed: February 24, 2004

Art Unit: 1648

For: GENETIC ENGINEERING OF  
STREPTAVIDIN-BINDING PEPTIDE  
TAGGED SINGLE-CHAIN VARIABLE  
FRAGMENT ANTIBODY TO VENEZUELAN  
EQUINE ENCEPHALITIS VIRUS

Examiner: S. B. Chen

**REVISED AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION AND  
NOTICE OF NON-COMPLIANCE**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action dated July 6, 2005 and the Notice of Non-Compliance dated December 23, 2005, please amend the above-identified U.S. patent application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks/Arguments** begin on page 6 of this paper.